Nausea octreotide

USP (Leupton) octreotide ace-tate [79517-01 ] 2H4O2 049 -66 1oOloS2 1019.24 (65) mestastatic carciuoid effects nausea diarrhea loose... 

Octreotide -synthetic peptide analogue of somatostatin -abdominal pain, nausea, vomiting, diarrhea -local injection site reactions -cholelithiasis -sweating, flushing -hyperglycemia (many patients will require insulin therapy)... 

Adverse effect of octreotide include nausea, vomiting, abdominal cramps and steatorrhea. 

Adverse effects of octreotide therapy include nausea, vomiting, abdominal cramps, flatulence, and steatorrhea with bulky bowel movements. Biliary sludge and gallstones may occur after 6 months of use in 20-30% of patients. However, the yearly incidence of symptomatic gallstones is about 1%. Cardiac effects include sinus bradycardia (25%) and conduction disturbances (10%). Pain at the site of injection is common, especially with the long-acting octreotide suspension. Vitamin B12 deficiency may occur with long-term use of octreotide. 

Severe hypertension with associated headache, nausea, and vomiting was reported within 2 weeks of administration of octreotide LAR 20 mg in a 26-year-old diabetic woman with autonomic neuropathy (6). Rechallenge with octreotide 75 pg resulted in a transient hypertensive episode lasting 3 hours. 

Diarrhea is common soon after starting octreotide but usually resolves within 2 weeks without specific treatment. In a randomized, double-blind, placebo-controlled trial in 203 mostly postmenopausal women with locally recurrent or metastatic breast carcinoma, all of whom were also taking tamoxifen, and who had estrogen-receptor positive and/or progesterone-receptor positive tumors, octreotide was added to the basic treatment in 99 cases (31). The adverse events experienced by 10% or more of the patients and attributed to octreotide were gastrointestinal diarrhea (53%), nausea (16%), and abdominal pain (11%) diarrhea occurred in only 11% of the controls. 

Originally isolated from the hypothalamus, somatostatin is a small polypeptide that is also found in neurons throughout the body, as well as in the intestine and pancreas. Somatostatin therefore predictably has a number of actions. Octreotide [awk TREE oh tide] is a synthetic octapeptide analog of somatostatin. It has a much longer half-life than the natural compound and has found use in the treatment of acromegaly caused by hormone-secreting tumors, and secretory diarrhea associated with tumors producing the vasoactive intestinal peptide (VIP). Adverse effects of octreotide treatment are flatulence, nausea, and steatorrhea. 

Octreotide Nausea and vomiting diarrhoea Steatorrhoea gallstones... 

Octreotide is a long-acting somatostatin analog that inhibits the secretion of serotonin, vasoactive intestinal peptide, gastrin, motilin, insulin, glucagons, secretin, and pancreatic polypeptide. It is used for the control of symptoms in patients with carcinoid and vasoactive intestinal peptide-secreting tumors (VIPomas). Its major toxicity is nausea and vomiting. 

Because octreotide inhibits many other gastrointestinal hormones, it has a variety of intestinal side effects. With prolonged use, gallbladder and biliary tract complications such as cholelithiasis have been reported. About 5% to 10% of patients complain of nausea, diarrhea, and abdominal pain. Local injection pain occurs with about an 8% incidence. With high doses, octreotide may reduce dietary fat absorption, leading to steatorrhea. 

The most common adverse effects of octreotide therapy are gastrointestinal disturbances such as diarrhea, nausea, abdominal cramps, malabsorption of fat, and flatulence.xhese effects are dose dependent and can be seen within a few hours of the first octreotide injection. Gastrointestinal adverse effects occur in approx-... 

GI side effects—including diarrhea, nausea, and abdominal pain—occur in up to 50% of patients receiving octreotide. In most patients, these symptoms diminish over time and do not require cessation of therapy. Approximately 25% of patients receiving octreotide develop gallstones, presumably due to decreased gallbladder contraction and GI transit time. In the absence of symptoms, gallstones are not a contraindication to continued use of octreotide. Compared to somatostatin, octreotide reduces insulin secretion to a lesser extent and only infrequently affects glycemic control. 

---